KPV Calculator

What Is KPV?

KPV is a synthetic tripeptide composed of three amino acids: lysine, proline, and valine. Its name is derived from the single-letter codes of those amino acids (K-P-V). KPV is the C-terminal fragment of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH) — specifically residues 11 through 13. While alpha-MSH is a much larger 13-amino-acid peptide that produces a broad range of effects, including pigmentation, appetite regulation, and inflammatory modulation, KPV isolates the anti-inflammatory portion of that molecule without the pigment-driving properties.

This is what makes KPV interesting in preclinical research: it is a small, comparatively stable molecule that carries the immunomodulatory signature of alpha-MSH without binding to the melanocortin receptors responsible for skin tanning. As a result, the literature frequently discusses KPV alongside peptides such as BPC-157 and Selank in the context of barrier function, mucosal repair, and anti-inflammatory activity. Unlike Melanotan compounds, which are also derived from the melanocortin family, KPV has no meaningful effect on pigmentation.

KPV is not a hormone in the classical sense and does not act on the hypothalamic-pituitary axis. It works predominantly at the local, cellular level, where it modulates inflammatory signaling pathways. Its low molecular weight allows researchers to study not only injectable administration but also oral and topical routes. The information presented here applies strictly to the research context; KPV is not an approved drug.

Mechanisms of Action

KPV exerts its biological activity primarily by dampening inflammatory signaling cascades. Unlike its parent peptide alpha-MSH, KPV appears to act largely independently of cell-surface receptors: research data suggest the tripeptide is taken up into the cell and intervenes in key signaling pathways intracellularly rather than docking onto an external receptor. The effects described in the preclinical literature include:

• Inhibition of the NF-kB pathway: NF-kB (nuclear factor kappa B) is a central transcription factor that drives the production of numerous pro-inflammatory proteins. Research shows that KPV reduces the activation and nuclear translocation of NF-kB, throttling the transcription of inflammatory genes. This is considered one of the principal mechanisms behind KPV's anti-inflammatory activity.
• Reduction of pro-inflammatory cytokines: In cell and animal models, KPV lowers the concentration of signaling molecules such as TNF-alpha, interleukin-1, and interleukin-6. These cytokines drive and sustain inflammatory responses, and reducing their levels dampens inflammatory activity without fully shutting down the immune response.
• Modulation of MAPK signaling: KPV interacts with the mitogen-activated protein kinase cascades, which are also involved in regulating inflammation and cellular stress. The combined action on NF-kB and MAPK explains the broad anti-inflammatory profile observed in preclinical models.
• Gut barrier research: A substantial portion of the KPV literature focuses on inflammatory bowel models. KPV is taken up by intestinal epithelial cells via a peptide transporter and reduces mucosal inflammation. This has been studied in colitis models, where KPV lowered inflammatory markers and supported the integrity of the epithelial barrier.
• Skin barrier research: Because KPV is a fragment of a skin-associated hormone, it is also studied in dermatological contexts. Preclinical work examines topical and systemic application in inflammatory skin models and in supporting the wound-healing phase, where excessive inflammation can delay the healing process.
• Antimicrobial properties: Like its parent hormone alpha-MSH, KPV demonstrates direct antimicrobial activity against certain bacteria and fungi in laboratory studies. This aspect remains an area of ongoing basic research.

Dosage Calculation

KPV does not typically require a titration ramp. Most research protocols use a fixed daily dose. Because it is a small tripeptide with a short half-life, some protocols use once-daily administration while others split the dose into two applications per day.

Standard Dosing Parameters

• Conservative dose: 100 mcg (0.10 mg) per application
• Standard dose: 200–250 mcg (0.20–0.25 mg) per application
• Higher range: 500–1000 mcg (0.50–1.00 mg) per application
• Frequency: Once daily, split into two partial doses if needed
• Typical syringe: 0.3 mL insulin syringe (29–31 gauge, 6–8 mm needle)

Example Calculation: 10 mg Vial with 2 mL BAC Water

A common vial size is 10 mg. Adding 2 mL of bacteriostatic water gives a concentration of 5 mg/mL (5,000 mcg/mL).

• 100 mcg dose: 100 ÷ 5000 = 0.02 mL (2 units on a U100 syringe)
• 200 mcg dose: 200 ÷ 5000 = 0.04 mL (4 units)
• 250 mcg dose: 250 ÷ 5000 = 0.05 mL (5 units)
• 500 mcg dose: 500 ÷ 5000 = 0.10 mL (10 units)

At 250 mcg once daily, a 10 mg vial provides 40 days of dosing. Use the KPV calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose. The calculator is also helpful when using a 10 mg vial, since concentration and syringe volume shift accordingly.

Reconstitution

KPV is supplied as a lyophilized (freeze-dried) powder in sealed vials. For injectable use it must be reconstituted with bacteriostatic water (BAC water) before application. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection should not be used for multi-dose vials because it contains no preservative.

Step-by-Step Reconstitution Protocol

1. Gather supplies: KPV vial, bacteriostatic water vial, alcohol swabs, a sterile draw needle (18–21 gauge), and your insulin syringe for later application.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa afterward.
3. Draw the desired volume of BAC water (2 mL is standard for a 5 mg vial) into the draw syringe.
4. Insert the needle into the KPV vial at an angle, directing the tip toward the inner glass wall rather than the lyophilized powder. A direct stream onto the powder cake can mechanically stress the peptide.
5. Slowly push the plunger so that the BAC water runs down the inside wall of the vial and gradually wets the powder from below.
6. Gently swirl or roll the vial between your palms until the powder is completely dissolved. The solution should appear clear and colorless. Do not shake or vortex, as strong shear forces can damage the peptide.
7. Label the vial with the reconstitution date and concentration (for example, "KPV 2.5 mg/mL — reconstituted [date]").

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it. The oral and topical routes also studied in research use different preparations that are outside the scope of this injection-focused guide.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage, where it remains stable for many months. Short-term storage at 2–8°C in a refrigerator is acceptable for several weeks. Keep away from light and moisture and do not leave at room temperature for extended periods.
• Reconstituted solution: Store in the refrigerator at 2–8°C. The solution is typically stable for approximately 28–30 days. Keep the vial upright and away from light, and write the reconstitution date prominently on the label. Discard the vial after roughly 30 days regardless of remaining volume.
• Do not freeze reconstituted peptide. Freeze-thaw cycles cause peptide aggregation and loss of activity. Once reconstituted, the vial must remain refrigerated throughout its entire use window.
• Transport: Use an insulated cooler with an ice pack for any travel lasting more than one to two hours. Commercial medication pouches maintain 2–8°C for 24–48 hours. Avoid exposure to temperatures above 25°C.

Side Effects and Safety Profile

KPV is regarded as a well-tolerated peptide in preclinical research. As a short tripeptide and a fragment of an endogenous hormone, it has not shown a pronounced toxicity profile in animal models. Robust human clinical trials are largely absent, however, which is why use remains strictly within the research domain and all statements should be assessed with appropriate caution.

Commonly Reported Observations

• Mild redness, transient swelling, or brief discomfort at the injection site. These reactions usually resolve within a few hours. Rotating the injection site reduces localized irritation.
• Occasionally, mild pressure or slight fatigue is reported after the first application. Such observations are nonspecific and generally self-limiting.
• With oral use in research protocols, mild gastrointestinal sensations are occasionally described and are typically minor.

Less Common or Theoretical Concerns

• Hypersensitivity reactions: As with any injectable peptide, allergic reactions are possible in principle. If a rash, itching, or swelling extends beyond the injection site, use should be discontinued.
• Immunomodulation: Because KPV dampens inflammatory signaling pathways, an interaction with other immunomodulatory substances is theoretically conceivable. The combined effect at the cellular and tissue level is not well characterized.
• Source purity: Impurities from low-quality synthesis can cause side effects that are not attributable to the peptide itself. Verified purity is therefore a central safety factor.

Contraindications

• Pregnancy and breastfeeding, due to insufficient safety data
• Known hypersensitivity to any component of the preparation
• Active autoimmune or infectious disease without medical supervision, since the effect of immunomodulation cannot be predicted in these contexts

No serious adverse events have been attributed to KPV in the published literature at standard research doses. Given the absence of large-scale human trials, caution is warranted and consultation with a qualified healthcare professional is strongly recommended.

Combinations and Stacks

KPV + BPC-157 — Gut and Barrier Focus

KPV is frequently considered alongside BPC-157 in research on the gastrointestinal barrier. The two peptides address complementary aspects: BPC-157 is one of the most extensively studied peptides for gastrointestinal repair and drives angiogenesis and mucosal healing, while KPV specifically dampens the inflammatory component through inhibition of NF-kB. In preclinical gut models, the regenerative orientation of BPC-157 complements the anti-inflammatory profile of KPV. View detailed dosing information for BPC-157 at the BPC-157 calculator.

KPV + Selank — Inflammation and the Stress Axis

Another combination discussed in research pairs KPV with Selank. Selank is studied primarily in the context of stress regulation and neuroimmune modulation. While KPV acts on the peripheral inflammatory burden, Selank addresses overlapping pathways at the neuroimmune level. Research protocols that combine both peptides treat them as two independent tools with separate focal points.

KPV + Thymosin Alpha-1 — Immune Context

In the broader immunological context, KPV is also positioned alongside Thymosin Alpha-1. Thymosin Alpha-1 is associated in research with the regulation of the immune response. The combination is of interest because KPV dampens inflammatory overactivation, while Thymosin Alpha-1 modulates immune balance at a different level. Each component should be reconstituted and dosed individually.

Frequently Asked Questions

Is KPV the same as alpha-MSH?

No. KPV is the C-terminal fragment of alpha-MSH and consists of only three amino acids, whereas alpha-MSH is a complete 13-amino-acid peptide hormone. KPV carries the anti-inflammatory portion of the molecule but lacks the pigment-driving properties of alpha-MSH, because it does not bind to the melanocortin receptors responsible for tanning.

Does KPV cause skin tanning?

Based on current research, no. Unlike Melanotan compounds, which are also derived from the melanocortin family, KPV has no meaningful effect on melanin production. Dermatological research on KPV focuses on inflammatory skin models and barrier function, not pigmentation.

Can KPV be taken orally?

In research, KPV is studied orally in addition to injectable use, particularly in gut models. Studies describe that KPV is taken up by intestinal epithelial cells via a peptide transporter, enabling a local effect in the gastrointestinal tract. For systemic research questions, subcutaneous administration is generally preferred.

How long does it take for KPV to show effects?

Because KPV has primarily been studied in preclinical models, no reliable statements about human time windows can be made. The underlying mechanism — dampening inflammatory signaling — acts relatively quickly at the cellular level, but the observable effect depends heavily on the specific model and endpoint. Any timing outside controlled studies is speculative.

Does KPV affect hormone levels?

KPV is not a hormone in the functional sense and does not act on the hypothalamic-pituitary axis. Based on the current research, it does not bind to the classical melanocortin receptors and affects neither the sex hormones nor thyroid or adrenal function. Post-cycle therapy is not relevant.

What vial size is common for KPV?

KPV is typically offered in 5 mg and 10 mg vials. The 5 mg size is practical for most research protocols, as it covers roughly 20 days at a daily dose of 250 mcg. Larger vials reduce the number of reconstitution events but must be used within the shelf-life window of the reconstituted solution.

Can KPV be mixed with BPC-157 in the same syringe?

It is safer to reconstitute and inject each peptide individually. The combined stability of KPV and BPC-157 in a shared solution is not well characterized. Two separate injections at the same or an adjacent site add only minor inconvenience while eliminating the risk of interaction or concentration errors.

What should I look for when buying KPV?

Verified purity is essential, ideally documented by a certificate of analysis (HPLC and mass spectrometry). Because KPV is a short peptide, synthesis byproducts can distort the actual activity profile. Also look for proper lyophilization and appropriate refrigerated logistics. KPV is offered strictly for research purposes.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. KPV is not an approved drug or medical treatment and is described strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.